L3VLUP
ProSign in

WRBY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

WRBYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • WRBY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterWRBYJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 20216 holders, $2.9bn40 holders, $24.1bn
Q4 20219 holders, $2.7bn33 holders, $25.2bn
Q1 20228 holders, $2.2bn35 holders, $28.2bn
Q2 20228 holders, $683m33 holders, $26.9bn
Q3 20225 holders, $490m36 holders, $25.4bn
Q4 20226 holders, $451m35 holders, $27.6bn
Q1 20235 holders, $341m42 holders, $24.5bn
Q2 20235 holders, $369m38 holders, $25.0bn
Q3 20237 holders, $436m37 holders, $18.9bn
Q4 20237 holders, $413m31 holders, $19.0bn
Q1 20247 holders, $362m32 holders, $19.7bn
Q2 20248 holders, $333m35 holders, $20.4bn
Q3 20248 holders, $364m28 holders, $22.3bn
Q4 20249 holders, $517m37 holders, $20.4bn
Q1 202510 holders, $334m32 holders, $20.5bn
Q2 20258 holders, $340m31 holders, $18.4bn
Q3 20259 holders, $408m32 holders, $23.7bn
Q4 20256 holders, $231m29 holders, $27.8bn
Q1 20268 holders, $203m34 holders, $35.6bn
Q2 20267 holders, $381m33 holders, $39.1bn
WRBY

Warby Parker Inc

Holders
8
Reported value
$340m
Buyers
2
Sellers
7

Breadth -5 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only WRBY (7)

Artisan Partners LP, Baillie Gifford & Co, Durable Capital Partners LP, First Eagle Investment Management LLC, Maverick Capital Ltd, PDT Partners LLC, Polen Capital Management LLC

Only JNJ (30)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →